Uganda's first $10M order for local ARVs

4 February 2008

Uganda's recently commissioned antiretroviral and anti-malarial drugs plant starts production with a bang, reports the East African Business Week, as the government places an order for a consignment of ARVs worth around $10.0 million.

The nation's Health Ministry is raising $4.3 million and other government departments will supply the remaining $5.7million to buy the drugs, a move that is believed will mark a new era in the management of HIV/AIDS in the country. The ministry of health is handling the procurement of ARVs which will be deployed in the national AIDS treatment program in which up to 100,000 Ugandans are getting free treatment.

Statistics indicate that, despite reaching 42% of the population in need of antiretroviral therapy in 2005, this number continues to grow each year, for example, rising to 129,000 in 2007 and projected to reach 238,000 in 2012 - far outstripping the capacity of the system to respond.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight